Onco Actu du 4 janvier 2017

	3.1.1 Tabac - e-cigs
FDA probes dangers of exploding e-cigarette batteries [AP] The U.S. Food and Drug Administration is probing the dangers of exploding batteries in e-cigarettes, following dozens of reports of devices that have combusted, overheated or caught fire and sometimes injured users.
	4. Dépistage, diagnostic et pronostic
Bayer Develops Companion Diagnostic Test for Cancer Patients Together with Leica Biosystems [Bayer] Bayer has entered into an agreement with Leica Biosystems to collaborate on the development of companion diagnostic tests based on tissue samples using RNAscope® (a multiplex nucleic acid hybridization technology) and immunohistochemistry for cancer patients.
Experts call for expansion of molecular imaging in precision cancer care [ecancer news] "We don't have a good framework yet for moving these potentially powerful diagnostic tools into routine clinical use," Mankoff said. "Among other things, we need to bring the imaging and oncology communities together to find the best way forward."
	4.2 Dép., diag. & prono. - Génome
Thousands Give DNA To Further Crowdsourced Breast Cancer Research Project [Hartford Courant] As the groundbreaking study enters its second year, more than 2,900 women and men have signed on to participate in the Metastatic Breast Cancer Project (MBCproject) since it launched Oct. 20, 2015.
Using genomics to improve detection of endometrial cancer [FierceBiotech] They discovered that 7 of the women had developed endometrial cancer and that all of them had significant gene mutations associated with the disease. However, 51 women who did not develop endometrial cancer also had the mutations, making it unclear how exactly the genetic abnormalities cause cancer in some women but not others.
	5. Traitements
New cancer drugs offer widely different benefits, study says [FiercePharma] “As calls for value-based healthcare grow, this analysis raises questions about how clinical benefits are measured by regulators, how regulatory guidance is used to inform clinical decisionmaking, and how much value is generated from spending in the oncology drug market,” the authors concluded.
A lasting immune impression could boost blood cancer treatments [Cancer Research UK] The team wondered whether switching on TLR7 in cancer could help the immune system remember the disease, offering long-term protection. The team treated mice with lymphoma with either obinutuzumab on its own, a TLR7-activating drug called R848, or the two combined.
	5.12 Immunothérapies
First Trial Underway, Jounce Preps IPO To Fund Immuno-Oncology Work [Xconomy] Jounce’s first study involves a cancer drug called JTX-2011. It began this past summer and should produce data next year. Jounce wants to develop drugs that boost the effectiveness of current immunotherapy treatments known as checkpoint inhibitors.
	5.12.1 Immunothérapies - partenariats
Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer [FiercePharma] The idea is that the vaccine will generate a tumor T-cell response, and Opdivo will prevent the tumor from hampering that response.
	5.12.2 Immunothérapies - CAR-T
Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6 [Kite] ITE-718 recognizes the MAGE A3 and MAGE A6 fragments bound to a Class II HLA (DPB1*04:01) and therefore has the potential to kill tumor cells both directly and indirectly through activation of the immune system given it incorporates a class II TCR.
	5.2 Pharma
FDA clears Glenmark’s HER2+ cancer drug for Phase I trial [European Pharmaceutical Review] Preclinical studies suggest GBR 1302 may have activity against a range of HER2-expressing tumour types, including breast, gastric and other cancers.
FDA Grants Bayer Priority Review for Stivarga® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer [Bayer] Stivarga is currently approved for the treatment of patients with metastatic colorectal cancer (mCRC) who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy, as well as the treatment of patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST), who were previously treated with imatinib mesylate and sutinib maleate.
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head [Gilead] During his 12 year tenure at Novartis he was involved in several worldwide drug approvals.
Alessandro Riva exits top Novartis oncology post, heads to a troubled — but wealthy — Gilead [EndPoints] In the cancer field, Gilead was forced to halt a slate of 6 studies for Zydelig in the spring of 2016 due to safety issues. And that came after the drug was clearly losing a race with J&J’s Imbruvica from J&J and AbbVie on leukemia and lymphoma.
	5.4 Traitements - Economie
NICE backs Roche’s Perjeta, but bars Kadcyla [PharmaTimes] The recommendation only stands as long as Roche provides the drug with the discount agreed in the patient access scheme.
	6. Lutte contre les cancers
The new face of US science [Nature] All too often, funding agencies and recipients fail to appreciate that grants do not just pay for research, they shape careers. To improve support for the research workforce, the characteristics of the labour pool must be understood. But too few data are collected, and the information that is available is not being used fully.